Related references
Note: Only part of the references are listed.SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
Katherine R. Tuttle et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis
Yue Zhou et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
DIPEPTIDYL-PEPTIDASE 4 INHIBITORS DID NOT IMPROVE RENAL ENDPOINTS IN ADVANCED DIABETIC KIDNEY DISEASE
Edy Kornelius et al.
ENDOCRINE PRACTICE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dicarbonyl Stress at the Crossroads of Healthy and Unhealthy Aging
Cecilia Nigro et al.
CELLS (2019)
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Pouya Saeedi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Pioglitazone downregulates Twist-1 expression in the kidney and protects renal function of Zucker diabetic fatty rats
Zijian Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Glycemic Targets: Standards of Medical Care in Diabetes-2019
William T. Cefalu et al.
DIABETES CARE (2019)
Maintenance of Kidney Metabolic Homeostasis by PPAR Gamma
Patricia Corrales et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke)
Shadi Yaghi et al.
CIRCULATION (2018)
The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease
Yun Jung Oh et al.
PLOS ONE (2017)
Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus
Yu-Hung Chang et al.
ACTA DIABETOLOGICA (2017)
Diabetes and Kidney Disease: Role of Oxidative Stress
Jay C. Jha et al.
ANTIOXIDANTS & REDOX SIGNALING (2016)
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor
R. A. DeFronzo et al.
DIABETES OBESITY & METABOLISM (2016)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
W. N. Kernan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Diabetes Shared Care Program and Risks of Cardiovascular Events in Type 2 Diabetes
Edy Kornelius et al.
AMERICAN JOURNAL OF MEDICINE (2015)
Thiazolidinediones and Risk of Long-Term Dialysis in Diabetic Patients with Advanced Chronic Kidney Disease: A Nationwide Cohort Study
Yu-Hsin Chen et al.
PLOS ONE (2015)
SUMOylation of PPARγ by Rosiglitazone Prevents LPS-Induced NCoR Degradation Mediating Down Regulation of Chemokines Expression in Renal Proximal Tubular Cells
Ying Lu et al.
PLOS ONE (2013)
Observation on Renal Outcomes in the Veterans Affairs Diabetes Trial
Lily Agrawal et al.
DIABETES CARE (2011)
Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis
Pantelis A. Sarafidis et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2010)
Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality
Steven E. Nissen et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
Faramarz Ismail-Beigi et al.
LANCET (2010)
Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats
Gang Jee Ko et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
PPAR gamma in Kidney Physiology and Pathophysiology
Eva Kiss-Toth et al.
PPAR RESEARCH (2008)
Peroxisome proliferator-activated receptor-gamma agonists attenuate the profibrotic response induced by TGF-beta 1 in renal interstitial fibroblasts
Weiming Wang et al.
MEDIATORS OF INFLAMMATION (2007)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial
H. C. Gerstein et al.
LANCET (2006)
Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms
Tatsuo Okada et al.
DIABETES (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
E Chiquette et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Preserving renal function in adults with hypertension and diabetes: A consensus approach
GL Bakris et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2000)
Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
K Isshiki et al.
DIABETES (2000)
Share Paper
